
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. demonstrates a positive trajectory in its financial outlook, particularly bolstered by the continued success of cabozantinib (Cabo) in treating various cancers, including renal cell carcinoma (RCC) and neuroendocrine tumors (NETs), supported by recent label expansions and favorable data from clinical trials. The promising performance of zanzalintinib, especially in the treatment of metastatic colorectal cancer (mCRC), provides a strong indication of growth potential beyond Cabo, reflecting confidence in Exelixis's future product pipeline. Overall, the firm’s ability to deliver statistically significant improvements in survival rates and its strong positioning in key markets suggest a robust foundation for sustained revenue growth and competitive advantage.
Bears say
Exelixis Inc. faces a significant financial challenge due to the anticipated patent cliff in 2031, which is projected to result in an 80% revenue decline by 2032, surpassing the Street's expectation of a 68% drop. The company is also exposed to various competitive risks, including potential market share erosion for its key drug cabozantinib in renal cell carcinoma and disappointing performance in new indications. Additionally, uncertainties surrounding approval timelines and the potential for generic entry could further jeopardize Exelixis's revenue stability and overall financial outlook.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares